Beth Israel Deaconess Medical Center
Infectious Disease fellowship · Boston, MA · Program website
Roster not collected yet. There's no list of this program's own faculty, trainees, or papers yet. Below is Beth Israel Deaconess Medical Center's research in infectious disease, which the program shares with other departments and affiliated hospitals.
About Beth Israel Deaconess Medical Centerinstitution-wide infectious disease research
Infectious Disease publications from Beth Israel Deaconess Medical Center and affiliated institutions, since 2022. Updated 2026-11-07; refreshed daily.
132
works per year
17th of 71 infectious disease fellowship programs
-27.7%
2-year growth
37th of 71 infectious disease fellowship programs
30.8%
in top 10% of field (works before 2025)
16th of 67 infectious disease fellowship programs
56.0%
cited above world average
16th of 67 infectious disease fellowship programs
Works per year · * 2026 so far
Infectious Diseases · 616
Infectious Disease research topics at Beth Israel Deaconess Medical Center
Papers in the window; each links to the list on OpenAlex.
- HIV/AIDS Research and Interventions 170
- SARS-CoV-2 and COVID-19 Research 143
- COVID-19 Clinical Research Studies 80
- Clostridium difficile and Clostridium perfringens research 38
- Tuberculosis Research and Epidemiology 37
- Antibiotic Use and Resistance 28
- Infection Control in Healthcare 21
- HIV-related health complications and treatments 14
Most cited at Beth Israel Deaconess Medical Center since 2024
All infectious disease papers there on OpenAlex
- SARS-CoV-2 viral clearance and evolution varies by type and severity of immunodeficiencyYijia Li et al. · Science Translational Medicine · 2024 · PubMed · cited 108
- Diagnostic yield as an important metric for the evaluation of novel tuberculosis tests: rationale and guidance for future researchTobias Broger et al. · The Lancet Global Health · 2024 · PubMed · cited 71
- Interim Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged ≥18 Years — VISION and IVY Networks, September 2023–January 2024Jennifer DeCuir et al. · MMWR Morbidity and Mortality Weekly Report · 2024 · PubMed · cited 70
- Doxycycline Postexposure Prophylaxis and Bacterial Sexually Transmitted Infections Among Individuals Using HIV Preexposure ProphylaxisMichael W. Traeger et al. · JAMA Internal Medicine · 2025 · PubMed · cited 58
- SARS-CoV-2 XBB.1.5 mRNA booster vaccination elicits limited mucosal immunityNinaad Lasrado et al. · Science Translational Medicine · 2024 · PubMed · cited 49
- Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity—IVY Network, 26 Hospitals, 18 October 2023–9 March 2024Kevin C. Ma et al. · Clinical Infectious Diseases · 2024 · PubMed · cited 42
- COVID-19 vaccines: Immune correlates and clinical outcomesShant H. Mahrokhian et al. · Human Vaccines & Immunotherapeutics · 2024 · PubMed · cited 40
- National Tuberculosis Coalition of America Guidelines for Respiratory Isolation and Restrictions to Reduce Transmission of Pulmonary Tuberculosis in Community SettingsMaunank Shah et al. · Clinical Infectious Diseases · 2024 · PubMed · cited 36
- Waning immunity and IgG4 responses following bivalent mRNA boostingNinaad Lasrado et al. · Science Advances · 2024 · PubMed · cited 35
- “This is an illness. No one is supposed to be treated badly”: community-based stigma assessments in South Africa to inform tuberculosis stigma intervention designIsabel Foster et al. · BMC Global and Public Health · 2024 · PubMed · cited 33